On the other hand, the oncomiR miR-21 promotes NFκB activation by targeting negative regulators in colon adenocarcinomas, as shown in evidence from diverse cell lines, xenograft mouse models, and gene expression profiling of patient tumor samples [279]. The gene discussed is NFKB1; the disease is neoplasm.